Is Prothena Corporation plc (NASDAQ:PRTA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Prothena Corporation plc at current levels.
Broken biotech with three shots on goal in Parkinson's, ATTR, and tau, trading below cash-plus-royalty math.
Where PRTA is headed
Prothena in mid-2028 looks nothing like the $507M orphan the market treats it as today. By then, Roche's Phase 3 PADOVA readout on prasinezumab will have landed (the pivotal event that either validates or vaporises the a-synuclein hypothesis in early Parkinson's), coramitug will be deep into its ATTR-CM Phase 3 against a Vyndaqel/Attruby duopoly that's already proving the market can support multiple $3-5B franchises, and BMS-986446 will have generated a Phase 2 tau readout that either confirms or kills the second leg of the Bristol partnership. Three independent, mechanistically distinct bets, each partnered with a top-five pharma, and the whole company priced at 1.65x book with $470M-ish of cash cushioning the runway.
Read the full Compass Direction on PRTA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $9.97).
See the full PRTA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Prothena Corporation plc (NASDAQ:PRTA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Prothena Corporation plc at current levels. Broken biotech with three shots on goal in Parkinson's, ATTR, and tau, trading below cash-plus-royalty math.
What is PRTA's Compass Score?
Prothena Corporation plc scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for PRTA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the PRTA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.